Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 116

1.

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions.

Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J, Redon P, Nilsson PM, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Grassi G.

J Hypertens. 2018 Apr 12. doi: 10.1097/HJH.0000000000001731. [Epub ahead of print]

PMID:
29652731
2.

Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment.

Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Redon J, Redon P, Antza C, Tsioufis K, Grassi G, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Nilsson PM.

J Hypertens. 2018 Apr 9. doi: 10.1097/HJH.0000000000001730. [Epub ahead of print]

PMID:
29634663
3.

Practical Recommendations of the Obesity Management Task Force of the European Association for the Study of Obesity for the Post-Bariatric Surgery Medical Management.

Busetto L, Dicker D, Azran C, Batterham RL, Farpour-Lambert N, Fried M, Hjelmesæth J, Kinzl J, Leitner DR, Makaronidis JM, Schindler K, Toplak H, Yumuk V.

Obes Facts. 2017;10(6):597-632. doi: 10.1159/000481825. Epub 2017 Dec 6.

4.

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 153: A 55-year-old woman with atypical multiple sclerosis and irritable bowel syndrome.

Fabian E, Schiller D, Toplak H, Brunner-Krainz M, Fazekas F, Schoefl R, Krejs GJ.

Wien Klin Wochenschr. 2018 Feb;130(3-4):151-160. doi: 10.1007/s00508-017-1291-y. Epub 2017 Nov 21. No abstract available.

5.

Obesity and Type 2 Diabetes: Two Diseases with a Need for Combined Treatment Strategies - EASO Can Lead the Way.

Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, Toplak H.

Obes Facts. 2017;10(5):483-492. doi: 10.1159/000480525. Epub 2017 Oct 12. Review.

6.

A Proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk.

Hebebrand J, Holm JC, Woodward E, Baker JL, Blaak E, Durrer Schutz D, Farpour-Lambert NJ, Frühbeck G, Halford JGC, Lissner L, Micic D, Mullerova D, Roman G, Schindler K, Toplak H, Visscher TLS, Yumuk V.

Obes Facts. 2017;10(4):284-307. doi: 10.1159/000479208. Epub 2017 Jul 22.

7.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

8.

Comment on the Paper by Uerlich et al: Obesity Management in Europe: Current Status and Objectives for the Future. Obes Facts 2016;9:273-283.

Hainer V, Tsigos C, Toplak H, Micic D.

Obes Facts. 2016;9(6):392-396. doi: 10.1159/000452249. Epub 2016 Nov 30. No abstract available.

9.

2015 Milan Declaration: A Call to Action on Obesity - an EASO Position Statement on the Occasion of the 2015 EXPO.

Frühbeck G, Sbraccia P, Nisoli E, Woodward E, Yumuk V, Farpour-Lambert NJ, Halford JG, Toplak H, Carruba MO.

Obes Facts. 2016;9(4):296-8. doi: 10.1159/000448234. Epub 2016 Aug 30. No abstract available.

10.

Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure.

Jordan J, Toplak H, Grassi G, Yumuk V, Kotsis V, Engeli S, Cuspidi C, Nilsson PM, Finer N, Doehner W.

J Hypertens. 2016 Sep;34(9):1678-88. doi: 10.1097/HJH.0000000000001013.

PMID:
27488547
11.

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspects.

Toplak H, Stauber R, Sourij H.

Diabetologia. 2016 Jun;59(6):1148-9. doi: 10.1007/s00125-016-3941-4. Epub 2016 Apr 7. No abstract available.

12.

[Antihyperglycemic treatment guidelines for diabetes mellitus type 2].

Clodi M, Abrahamian H, Drexel H, Fasching P, Föger B, Francesconi C, Hoppichler F, Kaser S, Kautzky-Willer A, Lechleitner M, Ludvik B, Prager R, Fröhlich-Reiterer E, Roden M, Säly C, Schernthaner G, Sourij H, Toplak H, Wascher TC, Weitgasser R.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S45-53. doi: 10.1007/s00508-016-0991-z. German.

PMID:
27052250
13.

Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications: A joint position statement issued by eight medical societies. 2016 update.

Toplak H, Ludvik B, Lechleitner M, Dieplinger H, Föger B, Paulweber B, Weber T, Watschinger B, Horn S, Wascher TC, Drexel H, Brodmann M, Pilger E, Rosenkranz A, Pohanka E, Oberbauer R, Traindl O, Roithinger FX, Metzler B, Haring HP, Kiechl S.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S216-28. doi: 10.1007/s00508-016-0993-x.

14.

[Obesity and type 2 diabetes].

Toplak H, Hoppichler F, Wascher TC, Schindler K, Ludvik B.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S196-200. doi: 10.1007/s00508-016-0986-9. Review. German.

PMID:
27052246
15.

[Nutrition for diabetic patients].

Schindler K, Brix J, Dämon S, Hoppichler F, Kruschitz R, Toplak H, Ludvik B.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S131-6. doi: 10.1007/s00508-015-0926-0. Review. German.

PMID:
27052240
16.

[Mental disorders and diabetes mellitus].

Abrahamian H, Kautzky-Willer A, Rießland-Seifert A, Fasching P, Ebenbichler C, Hofmann P, Toplak H.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S170-8. doi: 10.1007/s00508-015-0939-8. Review. German.

PMID:
27052238
17.

[Lipids--Diagnosis and therapy in diabetes mellitus].

Wascher TC, Paulweber B, Toplak H, Säly CH, Drexel H, Föger B, Hoppichler F.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S68-70. doi: 10.1007/s00508-015-0933-1. Review. German.

PMID:
27052223
18.

European Guidelines for Obesity Management in Adults.

Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity.

Obes Facts. 2015;8(6):402-24. doi: 10.1159/000442721. Epub 2015 Dec 5. Erratum in: Obes Facts. 2016;9(1):64.

19.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators.

N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.

20.

2014 EASO Position Statement on the Use of Anti-Obesity Drugs.

Toplak H, Woodward E, Yumuk V, Oppert JM, Halford JC, Frühbeck G.

Obes Facts. 2015;8(3):166-74. doi: 10.1159/000430801. Epub 2015 May 1. No abstract available.

Supplemental Content

Loading ...
Support Center